XOMA CorpNASDAQ:XOMA
- LAST PRICE20.2900
- TODAY'S CHANGE (%)-0.9500 (-4.4727%)
- Bid / Lots18.9800/ 2
- Ask / Lots23.7500/ 2
- Open / Previous Close20.0300 / 21.2400
- Day Range
- 52 Week Range
- Volume46,763
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XOMA |
|---|---|---|
| 09:33 ET | 1534 | 21 |
| 09:39 ET | 234 | 20.875 |
| 10:26 ET | 200 | 21.005 |
| 10:36 ET | 4510 | 20.22 |
| 10:38 ET | 100 | 20.5974 |
| 10:42 ET | 101 | 20.6037 |
| 10:56 ET | 200 | 20.5 |
| 11:02 ET | 100 | 20.625 |
| 11:18 ET | 101 | 20.625 |
| 11:25 ET | 312 | 21.125 |
| 12:17 ET | 100 | 20.66 |
| 12:19 ET | 100 | 20.66 |
| 12:21 ET | 300 | 20.75 |
| 12:24 ET | 200 | 20.85 |
| 12:26 ET | 200 | 20.755 |
| 12:28 ET | 100 | 20.73 |
| 12:30 ET | 200 | 20.715 |
| 12:32 ET | 242 | 20.715 |
| 12:33 ET | 100 | 20.715 |
| 12:35 ET | 100 | 20.705 |
| 12:37 ET | 400 | 20.74 |
| 12:42 ET | 490 | 20.74 |
| 12:44 ET | 300 | 20.81 |
| 12:46 ET | 400 | 20.785 |
| 12:48 ET | 100 | 20.745 |
| 12:50 ET | 100 | 20.745 |
| 12:53 ET | 200 | 20.755 |
| 12:55 ET | 200 | 20.755 |
| 01:00 ET | 200 | 20.755 |
| 01:02 ET | 200 | 20.72 |
| 01:15 ET | 100 | 20.71 |
| 01:24 ET | 100 | 20.22 |
| 01:29 ET | 1000 | 20.22 |
| 01:31 ET | 400 | 20.3 |
| 01:38 ET | 100 | 20.49 |
| 01:40 ET | 200 | 20.23 |
| 01:44 ET | 300 | 20.35 |
| 01:45 ET | 900 | 20.35 |
| 01:47 ET | 300 | 20.25 |
| 01:51 ET | 100 | 20.25 |
| 01:56 ET | 100 | 20.26 |
| 01:58 ET | 100 | 20.25 |
| 02:00 ET | 100 | 20.25 |
| 02:02 ET | 200 | 20.25 |
| 02:03 ET | 438 | 20.2 |
| 02:05 ET | 200 | 20.2 |
| 02:07 ET | 200 | 20 |
| 02:09 ET | 531 | 20.01 |
| 02:14 ET | 700 | 20.1 |
| 02:16 ET | 200 | 20.14 |
| 02:18 ET | 700 | 20.33 |
| 02:20 ET | 800 | 20.25 |
| 02:21 ET | 100 | 20.25 |
| 02:23 ET | 100 | 20.25 |
| 02:30 ET | 100 | 20.25 |
| 02:32 ET | 100 | 20.27 |
| 02:34 ET | 200 | 20.325 |
| 02:36 ET | 100 | 20.325 |
| 02:45 ET | 200 | 20.325 |
| 02:50 ET | 200 | 20.245 |
| 02:52 ET | 300 | 20.245 |
| 03:08 ET | 200 | 20.14 |
| 03:10 ET | 1100 | 20.02 |
| 03:12 ET | 100 | 20.01 |
| 03:14 ET | 100 | 20 |
| 03:15 ET | 400 | 19.74 |
| 03:17 ET | 2200 | 19.71 |
| 03:19 ET | 200 | 19.71 |
| 03:21 ET | 100 | 19.71 |
| 03:26 ET | 100 | 19.9 |
| 03:28 ET | 1007 | 19.93 |
| 03:32 ET | 150 | 19.945 |
| 03:44 ET | 375 | 20.0765 |
| 03:46 ET | 166 | 20.23 |
| 03:53 ET | 200 | 20.5 |
| 03:55 ET | 300 | 20.5 |
| 03:57 ET | 643 | 20.5 |
| 04:00 ET | 1869 | 20.29 |
Jan 6, 2023
XOMA Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 7:00PM ET on Friday Jan 06, 2023 by GlobeNewswire
7:00PM ET on Friday Jan 06, 2023 by GlobeNewswire
Jan 4, 2023
BRIEF-XOMA Appoints New Executive Leadership Team, from 7:40AM ET on Wednesday Jan 04, 2023 by Thomson Reuters
7:40AM ET on Wednesday Jan 04, 2023 by Thomson ReutersNew Executive Leadership Team Appointed to Accelerate XOMA's Differentiated Royalty Monetization Strategy, from 7:30AM ET on Wednesday Jan 04, 2023 by GlobeNewswire
7:30AM ET on Wednesday Jan 04, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
XOMA Corp | 243.2M | 57.5x | --- |
Urogen Pharma Ltd | 233.7M | -2.2x | --- |
Gritstone bio Inc | 264.3M | -2.3x | --- |
Y-mAbs Therapeutics Inc | 193.9M | -1.5x | --- |
Affimed NV | 185.3M | -2.1x | --- |
KemPharm Inc | 186.0M | -5.4x | --- |
Company Information
XOMA Corporation is a biotechnology royalty aggregator. The Company’s drug royalty aggregator business is focused on early to mid-stage clinical assets, primarily in Phase I and II. The Company has a portfolio of economic rights and royalty payments associated with partnered pre-commercial therapeutic candidates. It also acquires the economics associated with pre-commercial therapeutic candidates that are licensed to pharmaceutical or biotechnology companies. The Company has a portfolio of more than 70 assets. Its royalty portfolio includes NIS793, anti-transforming growth factor-beta (TGFb) antibody program; gevokizumab (VPM087), a clinical-stage anti-IL-1b product candidate; scalimab (CFZ533); mezagitamab (TAK-079); RZ358; AZD2936, a TIGIT/PD-1 bispecific antibody; MK-4830, and others. The Company’s portfolio also includes Ebopiprant (OBE022), an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor.
Contact Information
- Headquarters
- Suite 310, 2200 Powell StreetEMERYVILLE, CA, United States 94608
- Phone
- 510-204-7239
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board, Interim Chief Executive Officer, Principal Executive Officer
- Owen Hughes
- Chief Financial Officer, Senior Vice President - Finance
- Thomas Burns
- Chief Investment Officer
- Bradley Sitko
- Lead Independent Director
- W. Denman Van Ness
- Independent Director
- Heather Franklin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $243.2M |
|---|---|
Revenue (TTM) | $40.5M |
Shares Outstanding | 11.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.96 |
EPS | $0.35 |
Book Value | $12.54 |
P/E Ratio | 57.5x |
Price/Sales (TTM) | 6.0 |
Price/Cash Flow (TTM) | 18.4x |
Operating Margin | 47.33% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
